Comparison of Ga-DOTA-JR11 PET/CT with Dosimetric Lu-satoreotide Tetraxetan (Lu-DOTA-JR11) SPECT/CT in Patients with Metastatic Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2020 May 8

PMID 32378020

Citations 10

Authors

Simone Krebs

Joseph A ODonoghue

Evan Biegel

Bradley J Beattie

Diane Reidy

Serge K Lyashchenko

Jason S Lewis

Lisa Bodei

Wolfgang A Weber

Neeta Pandit-Taskar

Affiliations

Soon will be listed here.

Abstract

Purpose: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of Ga-DOTA-JR11 and Lu-satoreotide tetraxetan (Lu-DOTA-JR11) in patients with NETs.

Methods: As part of a prospective clinical trial, 20 patients with metastatic NETs underwent Ga-DOTA-JR11 PET/CT and serial imaging with Lu-satoreotide tetraxetan. PET/CT and SPECT/CT parameters for lesion uptake and absorbed dose of Lu-satoreotide tetraxetan in lesions were compared using linear regression analysis and Pearson correlation.

Results: A total of 95 lesions were analyzed on Ga-DOTA-JR11 PET/CT and Lu-satoreotide tetraxetan SPECT/CT. SUVs and tumor-to-normal-tissue ratios on PET/CT and SPECT/CT were significantly correlated (p < 0.01), but the degree of correlation was modest with Pearson correlation coefficients ranging from 0.3 to 0.7. Variation in intrapatient lesional correlation was observed. Nevertheless, in all patients, the lesion SUVpeak uptake ratio for Lu-satoreotide tetraxetan vs. Ga-DOTA-JR11 was high; even in those with low uptake on Ga-DOTA-JR11 PET/CT (SUVpeak ≤ 10), a ratio of 8.0 ± 5.2 was noted. Correlation of SUVpeak of Ga-DOTA-JR11 with projected Lu-satoreotide tetratexan-absorbed dose (n = 42) was modest (r = 0.5, p < 0.01), while excellent correlation of SUVpeak of Lu-satoreotide tetraxetan with projected Lu-satoreotide tetraxetan-absorbed dose was noted (r = 0.9, p < 0.0001).

Conclusion: Our study shows that Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience.

Citing Articles

Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting Sc, Cu and Ti.

Hindie E, Koster U, Champion C, Zanotti-Fregonara P, Morgat C EJNMMI Phys. 2024; 11(1):98.

PMID: 39572444 PMC: 11582248. DOI: 10.1186/s40658-024-00699-z.

The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?.

Imperiale A, Jha A, Meuter L, Nicolas G, Taieb D, Pacak K J Nucl Med. 2023; 64(5):682-684.

PMID: 36759198 PMC: 10152128. DOI: 10.2967/jnumed.123.265406.

Immunostimulatory effects of a subcritical water extract of .

Hattori K, Takagi H, Ogata Y, Yamada T, Horiba H, Fukata K Biomed Rep. 2022; 18(1):1.

PMID: 36544853 PMC: 9756285. DOI: 10.3892/br.2022.1583.

Relationships between uptake of [Ga]Ga-DOTA-TATE and absorbed dose in [Lu]Lu-DOTA-TATE therapy.

Stenvall A, Gustafsson J, Larsson E, Roth D, Sundlov A, Jonsson L EJNMMI Res. 2022; 12(1):75.

PMID: 36534192 PMC: 9763525. DOI: 10.1186/s13550-022-00947-2.

Peptide Receptor Radionuclide Therapy.

Hofland J, Brabander T, Verburg F, Feelders R, de Herder W J Clin Endocrinol Metab. 2022; 107(12):3199-3208.

PMID: 36198028 PMC: 9693835. DOI: 10.1210/clinem/dgac574.

References

Srirajaskanthan R, Kayani I, Quigley A, Soh J, Caplin M, Bomanji J . The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51(6):875-82. DOI: 10.2967/jnumed.109.066134. View

Krebs S, Pandit-Taskar N, Reidy D, Beattie B, Lyashchenko S, Lewis J . Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2018; 46(3):677-685. PMC: 6447060. DOI: 10.1007/s00259-018-4193-y. View

Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P . 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003; 30(4):510-8. DOI: 10.1007/s00259-003-1117-1. View

Bodei L, Cremonesi M, Grana C, Fazio N, Iodice S, Baio S . Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12):2125-35. DOI: 10.1007/s00259-011-1902-1. View

Wild D, Fani M, Del Pozzo L, Kaul F, Krebs S, Fischer R . Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014; 55(8):1248-52. DOI: 10.2967/jnumed.114.138834. View

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V . Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38(9):1659-68. DOI: 10.1007/s00259-011-1846-5. View

Cescato R, Waser B, Fani M, Reubi J . Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011; 52(12):1886-90. DOI: 10.2967/jnumed.111.095778. View

Delpassand E, Samarghandi A, Zamanian S, Wolin E, Hamiditabar M, Espenan G . Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014; 43(4):518-25. DOI: 10.1097/MPA.0000000000000113. View

Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L . The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017; 58(5):756-761. DOI: 10.2967/jnumed.116.185587. View

10.

Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P . Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003; 30(2):207-16. DOI: 10.1007/s00259-002-1023-y. View

11.

Reidy-Lagunes D, Pandit-Taskar N, ODonoghue J, Krebs S, Staton K, Lyashchenko S . Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist Lu-Satoreotide Tetraxetan. Clin Cancer Res. 2019; 25(23):6939-6947. PMC: 8382090. DOI: 10.1158/1078-0432.CCR-19-1026. View

12.

Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C . Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010; 54(1):37-51. View

13.

Kwekkeboom D, Kam B, Van Essen M, Teunissen J, van Eijck C, Valkema R . Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2009; 17(1):R53-73. DOI: 10.1677/ERC-09-0078. View

14.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

15.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H, Schwaiger M . Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2008; 36(1):48-52. DOI: 10.1007/s00259-008-0944-5. View

16.

Ezziddin S, Lohmar J, Yong-Hing C, Sabet A, Ahmadzadehfar H, Kukuk G . Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?. Clin Nucl Med. 2012; 37(6):e141-7. DOI: 10.1097/RLU.0b013e31823926e5. View

17.

Wild D, Fani M, Behe M, Brink I, Rivier J, Reubi J . First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011; 52(9):1412-7. DOI: 10.2967/jnumed.111.088922. View

18.

Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X . Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006; 103(44):16436-41. PMC: 1618814. DOI: 10.1073/pnas.0607761103. View

19.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

20.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View